Author:
Castelo Branco Patrícia Valéria,Soares Rossy-Eric Pereira,de Jesus Luís Cláudio Lima,Moreira Vanessa Ribeiro,Alves Hugo José,de Castro Belfort Marta Regina,Silva Vera Lucia Maciel,Ferreira Pereira Silma Regina
Funder
Fundação de Amparo à Pesquisa e ao Desenvolvimento Científico do Maranhão − FAPEMA
Subject
Health, Toxicology and Mutagenesis,Genetics
Reference39 articles.
1. Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives;Croft;Trans. R. Soc. Trop. Med. Hyg.,2006
2. Oxidative stress in human infectious diseases—present and current knowledge about its druggability;Wrenger,2013
3. FDA. Food and Drug Administration. Briefing Document for the Anti-Infective Drugs Advisory Committee Meeting. Miltefosine (Impavido®) for the Treatment of Visceral, Mucosal and Cutaneous Leishmaniasis. (2013) NDA 204,684.
4. Miltefosine for new world cutaneous leishmaniasis;Soto;Clin. Infect. Dis.,2004
5. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: a randomized and controlled trial;Machado;PloS Negl. Trop. Dis.,2010
Cited by
8 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献